FL-301
(NBL-015)

Anti-CLDN18.2 in gastric and pancreatic cancers

FL-301 antibody mechanism

FL-301 is a fully human monoclonal antibody that binds to and blocks Claudin18.2. In nonclinical models, FL-301 was shown to have 10-20x higher affinity to Claudin18.2 than the benchmark antibody zolbetuximab and specificity to both gastric and pancreatic tumors.

Through Fc engineering, FL-301 has been designed with enhanced antibody dependent cellular cytotoxicity, complement dependent cytotoxicity, and antibody dependent cellular phagocytosis, which are three mechanisms that can lead to improved cancer cell killing and greater potency relative to zolbetuximab in nonclinical models.